We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
151
Curis
CRIS
$3.73M
$161K 0.01%
50
– –
FONR
152
DELISTED
Fonar
FONR
$130K 0.01%
8,473
– –
GI
153
DELISTED
EndoChoice Holdings, Inc.
GI
$130K 0.01%
+25,000
New +$137K
MYGN icon
154
Myriad Genetics
MYGN
$298M
$125K 0.01%
3,333
+833
+33% +$31.4K
STRR
155
DELISTED
Star Equity Holdings
STRR
$124K 0.01%
500
– –
ADVM
156
DELISTED
Adverum Biotechnologies
ADVM
$103K 0.01%
+2,000
New +$112K
CLLS
157
Cellectis
CLLS
$344M
$82K 0.01%
2,996
– –
HLF icon
158
Herbalife
HLF
$1.3B
$77K 0.01%
+2,500
New +$64.5K
CPRX
159
DELISTED
Catalyst Pharmaceutical
CPRX
$60K 0.01%
51,200
-800,000
-94% -$1.24M
NSPH
160
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$28K ﹤0.01%
35,379
– –
ZBH icon
161
Zimmer Biomet
ZBH
$19.3B
$17K ﹤0.01%
+161
New +$15.6K
CAPR icon
162
Capricor Therapeutics
CAPR
$544M
$10K ﹤0.01%
400
– –
CDMO
163
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$10K ﹤0.01%
+3,476
New +$18.6K
SCMP
164
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$8K ﹤0.01%
759
– –
INGN icon
165
Inogen
INGN
$148M
$6K ﹤0.01%
125
– –
DCOY
166
Decoy Therapeutics
DCOY
$1.97M
– –
0
– –
AFMD
167
DELISTED
Affimed
AFMD
– –
-86,882
Closed -$6.19M
AXDX
168
DELISTED
Accelerate Diagnostics
AXDX
– –
-75
Closed -$16K
BIIB icon
169
Biogen
BIIB
$32.7B
– –
-648
Closed -$199K
CI icon
170
Cigna
CI
$74.2B
– –
-20,000
Closed -$2.93M
COR icon
171
Cencora
COR
$62.6B
– –
-2,030
Closed -$211K
CRVL icon
172
CorVel
CRVL
$3.55B
– –
-15,345
Closed -$225K
CYH icon
173
Community Health Systems
CYH
$412M
– –
-8,136
Closed -$178K
ENSG icon
174
The Ensign Group
ENSG
$10.5B
– –
-9,347
Closed -$198K
IBRX icon
175
ImmunityBio
IBRX
$8.74B
– –
-10,000
Closed -$173K
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.